General Anesthesia vs. Local Anesthesia During Endovascular Treatment for Acute Large Vessel Occlusion: A Propensity Score-Matched Analysis

Hongxing Han¹, Yu Wang¹, Hao Wang¹, Hongyang Sun¹, Xianjun Wang¹, Jian Gong¹, Xiaochuan Huo², Qiyi Zhu¹ and Fengyuan Che¹*

¹ Department of Neurology, Linyi People's Hospital, Linyi, China, ² Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Objective: To date, no consensus still exists on the anesthesia strategy of endovascular treatment (EVT) for acute ischemic stroke (AIS) due to large vessel occlusion (LVO). We aimed to compare the 90-day outcomes, puncture-to-recanalization time (PRT), successful recanalization rate, and symptomatic intracranial hemorrhage (sICH) of patients undergoing general anesthesia (GA) or local anesthesia (LA) ± conscious sedation (CS) during the procedure.

Methods: We selected patients from the Acute Ischemic Stroke Cooperation Group of Endovascular Treatment (ANGEL) registry and divided them into the GA group and the LA ± CS group. The two groups underwent 1:1 matching under propensity score matching (PSM) analysis. Then, we compared the primary outcome including the 90-day modified Rankin Scale (mRS) 0–2, secondary outcome including the 90-day mRS, the 90-day mRS 0–1, the 90-day mRS 0–3, PRT, and successful recanalization rate as well as the safety outcome including sICH, any ICH, and 90-day mRS 6.

Results: Among the 705 enrolled patients, 263 patients underwent GA and 442 patients underwent LA ± CS. After 1:1 PSM according to the baseline characteristics, each group has 216 patients. Patients with GA had the higher median 90-day mRS [3 (1–5) vs. 2 (1–4), p <0.001], the lower 90-day mRS 0–2 rate (43.5 vs. 56.5%, p = 0.007), higher mortality (19.9 vs.10.2%, p = 0.005), and longer PRT [92 (60–140) vs. 70 (45–103) min, p < 0.001]. There were no differences in sICH and successful recanalization rate between both the groups.

Conclusion: In the real-world setting, LA ± CS might provide more outcomes benefits than GA in patients with AIS-LVO during the procedure.

Keywords: general anesthesia, local anesthesia, endovascular treatment, large vessel occlusion, propensity score matching
INTRODUCTION

Endovascular treatment (EVT) has become the standard for acute ischemic stroke (AIS) due to large vessel occlusion (LVO) (1–5). However, the most suitable anesthetic approach is still unknown. Recently, three well-known randomized controlled trials (RCTs) [Sedation vs Intubation for Endovascular Stroke Treatment (SIESTA), General or Local Anesthesia in Intra Arterial Therapy (GOLIATH), and Anesthesia During Stroke (ANSTROKE)] showed no significant difference in the outcome between different anesthetic approaches (6–8). Surprisingly, a meta-analysis of these three trials demonstrated different results; the use of protocol-based general anesthesia (GA) was significantly associated with less disability at 3 months (9). Conversely, analysis from the Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials (HERMES) collaborators demonstrated an association between poor outcome and GA (10). The finding from the Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke (DEFUSE 3) trial post-hoc analysis supported this result (11).

In a real-world scenario, the result might be different. Hence, the objective of this study was to compare the safety and efficacy outcomes between different anesthetic approaches, mainly GA vs. local anesthesia (LA) ± conscious sedation (CS) in patients with AIS-LVO undergoing EVT using data from the prospective multicenter Acute Ischemic Stroke Cooperation Group of Endovascular Treatment (ANGEL) registry.

METHODS

Patient Population and Data Collection

We retrospectively reviewed patients from a multicenter, prospective study of the ANGEL registry from June 2015 to December 2017 (12). Inclusion criteria in this study were described as the following: (1) Age more than 18 years; (2) Clinical diagnosis of ischemic stroke in which the stroke symptoms last for more than 30 min and no improvement prior to treatment; (3) The modified Rankin Scale (mRS) less than 2 before the current stroke; (4) Large vessel occlusion in the internal carotid artery (ICA), middle cerebral artery (MCA) (M1/M2 segment), and anterior cerebral artery (ACA); and (5) Informed consent form was obtained from the patient or legally authorized representative of the patient after receiving information about data collection.

Of all the patients, we excluded 210 patients due to posterior circulation stroke (n = 203) and no thrombectomy procedure [only digital subtraction angiography (DSA) or fragment, n = 7]. Finally, we classified 705 patients with GA (n = 263) and LA ± CS (n = 442). There were 61 (8.7%) patients who received CS in this study. GA was defined as induction and maintenance with sedation drugs, analgesic agents, and muscle relaxants, with controlled ventilation under tracheal intubation or laryngeal mask, from the time of puncture to the end of the procedure. CS was defined as LA and spontaneous breathing, with administration of sedatives during the procedure. LA is defined as subcutaneous anesthesia at the arterial puncture site with or without administration of sedatives throughout the procedure (13).

We recorded the demographics, medical history, prior treatment [antiplatelet therapy and intravenous thrombolysis (IVT)], systolic blood pressure (SBP), the National Institutes of Health Stroke Scale (NIHSS) score, the Alberta Stroke Program Early CT Score (ASPECTS) (14), occlusion sites [ICA, MCA (M1, M2/M3), ACA, and tandem occlusion] (15), the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) stroke subtypes (16), procedural characteristics, and the time points of working flow of the patient. All the pretreatment imaging data, including noncontrast CT, MRI, and DSA images during EVT and follow-up CT or MRI of the head, were anonymized and reviewed centrally by two independent physicians. A consensus between the physicians was obtained to resolve any disagreements; if no agreement was achieved, then a third physician blinded to this study was introduced for a final consensus.

Outcomes

The primary functional outcome was the 90-day mRS 0–2. Meanwhile, the safety endpoints were symptomatic intracranial hemorrhage (sICH) within 24 h post hours, which was diagnosed according to the European Cooperative Acute Stroke Study (ECASS-II) (17), any ICH within 24 h post-EVT, and mortality (mRS 6). Secondary outcomes included the 90-day mRS, the 90-day mRS 0–1, the 90-day mRS 0–3, successful recanalization of the modified Tissue Thrombolysis in Cerebral Ischemia (mTICI) 2b/3, and time from puncture to recanalization (18). At 3 months after endovascular therapy, we assessed the prognoses of all the patients through telephone follow-up. The follow-up was based on a shared standardized interview protocol and centrally conducted by a third-party Clinical Research Organization (CRO) blinded to the clinical details or anesthesia method.

Statistical Analysis

We described the categorical variables as numbers and percentages. We expressed the continuous variables as median with [interquartile range (IQR)]. We use the Wilcoxon rank-sum test for continuous variables and the Pearson’s chi-squared test or the Fisher’s exact test for categorical variables to perform univariate analysis to find the different characteristics between the GA and LA groups. Then, we performed propensity score matching (PSM) analysis using the caliper size of 0.02 to reduce selection bias and confounding variables between the two groups at a 1:1 ratio. All the significant baseline characteristics in univariate analysis (p < 0.05) and the baseline variables likely to influence the outcome were in the multivariate logistic regression model to calculate the propensity score including age, SBP, the NIHSS, the ASPECTS, IVT, and antiplatelet therapy before EVT, large artery atherosclerosis (LAA) stroke subtype, cardioembolism (CE) stroke subtype, tandem lesion, occlusion location, and time from door to puncture. Following the score generation, the neighboring matching algorithm without replacement was used to match the GA group and the LA ± CS group. After PSM, we used the same statistical methods to compare the two groups. A p < 0.05 (two-sided) was considered as statistically significant. We used the SPSS version 25.0 (IBM Incorporation, Armonk, New York, USA) to analyze the data.
### TABLE 1 | Comparison of baseline, procedure, and outcome characteristics between the two groups before PSM.

| Variables/c clinical findings | All Patients (n = 705) | GA (n = 263) | LA ± CS (n = 442) | P-value |
|-------------------------------|------------------------|--------------|-------------------|---------|
| **Age, y, median (IQR)**     | 64 (55–73)             | 65 (58–73)   | 64 (55–73)        | 0.170   |
| **Men, n (%)**               | 495 (64.5)             | 165 (62.7)   | 290 (65.6)        | 0.441   |
| **Medical history, n (%)**   |                        |              |                   |         |
| Hypertension                 | 364 (51.6)             | 131 (49.8)   | 233 (52.7)        | 0.455   |
| Diabetes mellitus            | 107 (15.2)             | 35 (13.3)    | 72 (16.3)         | 0.286   |
| Atrial fibrillation          | 145 (20.6)             | 57 (21.7)    | 88 (19.9)         | 0.575   |
| Stroke                       | 72 (10.2)              | 25 (9.5)     | 47 (10.6)         | 0.632   |
| Current smoking              | 237 (33.6)             | 87 (33.1)    | 150 (33.9)        | 0.816   |
| Current drinking             | 101 (14.3)             | 40 (15.2)    | 61 (13.8)         | 0.606   |
| **Prior treatment, n (%)**   |                        |              |                   |         |
| Antiplatelet therapy         | 150 (21.3)             | 72 (27.4)    | 78 (17.6)         | 0.002   |
| IVT                          | 263 (37.3)             | 63 (24.0)    | 143 (32.4)        | 0.018   |
| **Baseline measurements**    |                        |              |                   |         |
| SBP, mmHg                    | 145 (130–161)          | 147 (130–164)| 144 (130–160)     | 0.287   |
| Admission NIHSS, median (IQR)| 15 (10–20)             | 17 (13–21)   | 13 (9–18)         | <0.001  |
| ASPECTS, median (IQR)        | 8 (7–8)                | 8 (7–8)      | 8 (7–8)           | 0.024   |
| **Occlusion site, n (%) 0.093** | 126 (17.9)             | 35 (13.3)    | 91 (20.6)         | 0.015   |
| ICA                          | 285 (40.4)             | 113 (43.0)   | 172 (38.9)        |         |
| M1                           | 333 (47.2)             | 128 (48.7)   | 205 (46.4)        |         |
| M2/3                         | 82 (11.6)              | 21 (8.0)     | 61 (13.8)         |         |
| ACA                          | 5 (0.7)                | 1 (0.4)      | 4 (0.9)           |         |
| Tandem occlusion             | 126 (17.9)             | 35 (13.3)    | 91 (20.6)         | 0.015   |
| **Stroke subtype, n (%)**    |                        |              |                   |         |
| LAA                          | 486 (68.9)             | 164 (62.4)   | 322 (72.9)        | 0.004   |
| CE                           | 144 (20.4)             | 71 (27.0)    | 73 (16.5)         | 0.001   |
| **Procedure process, n (%)** |                        |              |                   |         |
| GP IIb/IIIa receptor inhibitor| 213 (30.2)             | 106 (40.3)   | 107 (24.2)        | <0.001  |
| Stent retriever              | 528 (74.9)             | 237 (90.1)   | 291 (65.8)        | <0.001  |
| Aspiration                   | 51 (7.2)               | 24 (9.1)     | 27 (6.1)          | 0.135   |
| IAT                          | 230 (32.6)             | 82 (31.2)    | 148 (33.5)        | 0.528   |
| Angioplasty                  | 53 (7.5)               | 18 (6.8)     | 35 (7.9)          | 0.601   |
| Stenting                     | 98 (13.9)              | 43 (16.3)    | 55 (12.4)         | 0.147   |
| **Time intervals, min, median (IQR)** | 180 (95–270)           | 180 (105–255)| 180 (90–278.5)    | 0.642   |
| Onset-to-door time           | 110 (69.5–156)         | 115 (74–165) | 105 (57–140)      | 0.007   |
| Onset-to-recanalization time | 385 (300–505)          | 393.5 (301.75–487.25) | 380 (296–610) | 0.655   |
| **Primary outcome, n (%)**   |                        |              |                   |         |
| 90-day mRS 0–2               | 369 (52.3)             | 107 (40.7)   | 262 (59.3)        | <0.001  |
| **Secondary outcomes**       |                        |              |                   |         |
| 90-day mRS 0–1, n (%)        | 3 (1–4)                | 3 (1–5)      | 2 (1–4)           | <0.001  |
| 90-day mRS 0–3, n (%)        | 292 (41.4)             | 82 (31.2)    | 210 (47.5)        | <0.001  |
| Puncture-to-recanalization time, median (IQR) | 80 (50–112)           | 89.5 (60–140) | 75 (50–110) | <0.001  |
| Successful recanalization (mTICI 2b/3), n (%) | 649 (92.1)            | 244 (92.8)   | 405 (91.6)        | 0.586   |
| **Safety outcomes, n (%)**   |                        |              |                   |         |
| sICH                         | 44 (6.2)               | 22 (8.4)     | 22 (5.0)          | 0.072   |
| Any ICH                      | 166 (23.5)             | 69 (26.2)    | 97 (21.9)         | 0.194   |
| 90-day mRS 6                 | 110 (15.6)             | 56 (21.3)    | 54 (12.2)         | 0.001   |

PSM, propensity score matching; IQR, interquartile range; IVT, intra-venous thrombolysis; NIHSS, National Institutes of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Score; ICA, internal carotid artery; M1, middle cerebral artery M1 segment; M2, middle cerebral artery M2 segment; M3, middle cerebral artery M3 segment; ACA, anterior cerebral artery; SBP, systolic blood pressure; LAA, large artery atherosclerosis; CE, cardioembolism; IAT, intra-arterial thrombolysis; ICH, intracranial hemorrhage; sICH, symptomatic ICH; mRS, modified Rankin Scale; GA, general anesthesia; LA, local anesthesia, CS, conscious sedation. Bold values indicates statistical significance.
RESULTS

Table 1 shows that 705 patients with AIS in anterior circulation underwent EVT were included in this study. During EVT, 263 patients received GA and 442 patients received LA (Figure 1). Antiplatelet therapy was significantly different before EVT, IVT before EVT, the admission NIHSS, the admission ASPECTS, tandem occlusion, LAA subtype, CE subtype, and time from door to puncture between the two groups. Compared to the LA ± CS group, patients in the GA group had the higher median NIHSS, the longer median time from door to puncture, and the median ASPECTS. Besides antiplatelet therapy and CE subtype, IVT before EVT, LAA subtype, and tandem occlusion occurred less frequently in the GA group.

Table 2 shows that 216 patients in each group were matched 1:1 according to the baseline characteristics. After PSM, the covariates were statistically similar between the two groups. The proportion of patients receiving antiplatelet therapy (25.5 vs. 28.2%, \( p = 0.515 \)) and IVT (28.2 vs. 29.6%, \( p = 0.750 \)) before EVT in the GA group was similar to the LA ± CS group. There was no significant difference in tandem occlusion (14.8 vs. 13.9%, \( p = 0.784 \)), LAA subtype (67.1 vs. 47.3%, \( p \))
### TABLE 2 | Comparison of baseline, procedure, and outcome characteristics between the two groups after PSM.

| Variables/clinical findings | All patients (n = 432) | GA (n = 216) | LA ± CS (n = 216) | P-value |
|-----------------------------|-----------------------|--------------|-------------------|---------|
| Age, y, median (IQR)        | 64 (55–73)            | 64 (56–73)   | 63 (54–74.8)      | 0.472   |
| Men, n (%)                  | 277 (64.1)            | 137 (63.4)   | 140 (64.8)        | 0.763   |
| **Medical history, n (%)**  |                       |              |                   |         |
| Hypertension                | 217 (105)             | 105 (48.6)   | 112 (51.9)        | 0.501   |
| Diabetes mellitus           | 69 (16.0)             | 31 (14.4)    | 38 (17.6)         | 0.358   |
| Atrial fibrillation         | 92 (21.3)             | 41 (19.0)    | 51 (23.8)         | 0.240   |
| Stroke                      | 44 (10.2)             | 20 (9.3)     | 24 (11.1)         | 0.525   |
| Current smoking             | 155 (35.9)            | 78 (36.1)    | 77 (35.6)         | 0.920   |
| Current drinking            | 62 (14.4)             | 36 (16.7)    | 26 (12.0)         | 0.170   |
| **Prior treatment, n (%)**  |                       |              |                   |         |
| Antiplatelet therapy        | 116 (26.9)            | 55 (25.5)    | 61 (28.2)         | 0.515   |
| IV thrombolysis             | 105 (24.1)            | 52 (24.2)    | 53 (24.2)         | 0.821   |
| **Baseline measurements, median (IQR)** |         |              |                   |         |
| Systolic blood pressure, mmHg | 146 (130–162)        | 148.5 (130.0–163.5) | 145.5 (130.0–162.0) | 0.738   |
| Admission NIHSS             | 16 (13–21)            | 16 (13–21)   | 16 (13–22)        | 0.589   |
| ASCPECTS, median            | 8 (7–8)               | 8 (7–8)      | 8 (7–8)           | 0.523   |
| **Occlusion site, n (%)**   |                       |              |                   |         |
| ICA                         | 174 (40.3)            | 94 (43.5)    | 80 (37.0)         | 0.163   |
| M1                          | 205 (47.5)            | 102 (47.2)   | 103 (47.7)        | 1.000   |
| M2/3                        | 51 (11.8)             | 19 (8.8)     | 32 (14.8)         | 0.240   |
| ACA                         | 2 (0.5)               | 1 (0.5)      | 1 (0.5)           | 1.000   |
| Tandem occlusion            | 62 (14.4)             | 32 (14.8)    | 30 (13.9)         | 0.784   |
| **TOAST, n (%)**            |                       |              |                   |         |
| LAA                         | 275 (63.7)            | 145 (67.1)   | 130 (67.3)        | 0.134   |
| CE                          | 100 (23.1)            | 50 (23.1)    | 50 (23.1)         | 1.000   |
| **Procedure process, n (%)**|                       |              |                   |         |
| GP IIb/IIIa receptor inhibitor| 147 (34.0)            | 83 (38.4)    | 64 (29.8)         | 0.054   |
| Stent retriever             | 357 (82.6)            | 192 (88.9)   | 165 (76.4)        | 0.001   |
| Aspiration                  | 40 (9.3)              | 20 (9.3)     | 20 (9.3)          | 1.000   |
| IA thrombolysis             | 118 (27.3)            | 73 (33.8)    | 45 (20.8)         | 0.002   |
| Angioplasty                 | 40 (9.3)              | 18 (8.3)     | 22 (10.2)         | 0.507   |
| Stenting                    | 69 (16.0)             | 38 (17.6)    | 31 (14.4)         | 0.358   |
| **Time intervals, min, median (IQR)** |         |              |                   |         |
| Onset-to-door time          | 160 (90–255)          | 170 (90.5–241.0) | 154.0 (87.8–266.0) | 0.510   |
| Door-to-puncture time       | 106 (60–150)          | 110 (60–145) | 104.5 (65.0–150.0) | 0.669   |
| Onset-to-recanalization time| 374.5 (284.5–470)     | 397 (300–487) | 360 (277–460)     | 0.012   |
| **Primary outcome, n (%)**  |                       |              |                   |         |
| 90-day mRS 0–2              | 216 (50.0)            | 94 (43.5)    | 122 (56.5)        | 0.007   |
| **Secondary outcomes**      |                       |              |                   |         |
| 90-day mRS, median (IQR)    | 3 (1–4)               | 3 (1–5)      | 2 (1–4)           | <0.001  |
| 90-day mRS 0–1, n (%)       | 169 (39.1)            | 72 (33.3)    | 97 (44.9)         | 0.014   |
| 90-day mRS 0–3, n (%)       | 276 (63.9)            | 125 (57.9)   | 151 (69.9)        | 0.009   |
| Puncture-to-recanalization time, median (IQR) | 80 (50–115)          | 92 (60–140)  | 70 (45–103)       | <0.001  |
| Successful recanalization (mTICI 2b/3), n (%) | 390 (90.3)            | 200 (92.8)   | 190 (88.0)        | 0.104   |
| **Safety outcomes, n (%)**  |                       |              |                   |         |
| Any ICH                     | 112 (25.9)            | 56 (25.9)    | 56 (25.9)         | 1.000   |
| sICH                        | 28 (6.5)              | 17 (7.9)     | 11 (5.1)          | 0.241   |
| 90-day mRS 6                | 65 (15.0)             | 43 (19.9)    | 22 (10.2)         | 0.005   |

PSM, propensity score matching; IQR, interquartile range; IVT, intra-venous thrombolysis; NIHSS, National Institutes of Health Stroke Scale; ASCPECTS, Alberta Stroke Program Early CT Score; ICA, internal carotid artery; M1, middle cerebral artery M1 segment; M2, middle cerebral artery M2 segment; M3, middle cerebral artery M3 segment; ACA, anterior cerebral artery; SBP, systolic blood pressure; LAA, large artery atherosclerosis; CE, cardioembolism; IAT, intra-arterial thrombolysis; ICH, intracranial hemorrhage; sICH, symptomatic ICH; mRS, modified Rankin Scale; GA, general anesthesia; LA, local anesthesia, CS, conscious sedation. Bold values indicates statistical significance.
FIGURE 2 | Shift on the 90-day mRS score stratified by LA and GA before PSM. PSM, propensity score matching; mRS, modified Rankin Scale.

FIGURE 3 | Shift on the 90-day mRS score stratified by LA ± CS and GA after PSM. PSM, propensity score matching; mRS, modified Rankin Scale; GA, general anesthesia; LA, local anesthesia; CS, conscious sedation.
showed different results ([21 vs. 23.1%], \( p = 1.000 \) between the two groups. The admission NIHSS (16 vs. 16, \( p = 0.589 \)), the ASPECTS (8 vs. 8, \( p = 0.523 \)), and time from door to puncture (110 vs. 104.5 min, \( p = 0.669 \)) were similar between the two groups.

The propensity score-adjusted outcomes of the two groups are shown in Table 2. Time from puncture to recanalization (92 vs. 70 min, \( p = 0.000 \)) and time from onset to recanalization (397 vs. 360 min, \( p = 0.012 \)) were longer in the GA group than the LA ± CS group. The median mRS at 90 days was higher in the GA group than the LA ± CS group (3 vs. 2, \( p = 0.000 \)). Compared to the LA ± CS group, excellent outcome rate at 90 days (33.3 vs. 44.9%, \( p = 0.014 \)), good outcome rate at 90 days (43.5 vs. 56.5%, \( p = 0.007 \)), and favorable outcome rate at 90 days (57.9 vs. 69.9%, \( p = 0.009 \)) were lower, while mortality at 90 days (19.9 vs. 10.2%, \( p = 0.005 \)) was higher in the GA group ([Figures 2, 3]). There was no difference in successful recanalization rate, any ICH incidence, and sICH incidence between the two groups.

**DISCUSSION**

In this multicenter study, in patients with AIS-LVO who had successful recanalization, LA may provide more functional benefit at 3 months follow-up than GA. A shorter time workflow from LA might attribute to this outcome result.

There is still inconsistency regarding the anesthetic approach during EVT. A study using PSM to reduce the impact of confounding factors reported that CS might reduce the in-hospital mortality, rates of complications, hospital costs, and lengths of stay than those who had GA ([19]). Another cohort study reported a similar result ([20]). In contrast, the Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment (SWIFT PRIME) investigators ([21]) demonstrated that GA has a comparable time to treatment initiation and successful revascularization. Although, their study also demonstrated the negative effect of GA such as lower rates of functional independence and an increase in peri-procedural hypotension and postoperative pneumonia.

Later, three well-known RCTs demonstrated that anesthesia patterns might not significantly impact clinical treatment after EVT ([7–9]). However, the lack of sample size and centers involved limited the result to be generalized into the global population. Surprisingly, the meta-analysis of these three RCTs showed different results ([9]). GA is associated with clinical benefits in this study. The higher reperfusion rates in the GA group might attribute this result, suggesting that more optimal procedural condition during EVT is essential to the functional outcome.

On the contrary, a meta-analysis of individual data by the HERMES collaborators demonstrated that the non-GA approach showed better functional outcomes after EVT than those with the GA approach ([10]). Nevertheless, the largely unbalanced baseline parameters increase the risk for bias and confounding. Furthermore, the incomplete anesthesia pattern and hemodynamic management information further limited their interpretability.

Particular caution is needed when interpreting those results of studies. Either GA or non-GA both has advantages and disadvantages. GA may have the advantage in achieving a higher recanalization rate, as operators were more convenient to perform more complex EVT procedures confronting complex lesions in the presence of patient agitation and discomfort. Besides, the circumstances might lower the probability of procedural complications such as arterial perforation. These advantages might be less provided by non-GA ([22]). On the other hand, hypotension and blood pressure variability were more common in those who had GA, exacerbating the functional outcomes ([9, 22]).

While most studies compared the effect of GA and non-GA, the most non-GA approach was CS. To date, there is still a lack of study investigating the impact of LA in patients with AIS-LVO undergoing EVT. Recently, only two studies using PSM analysis investigated the impact of LA and non-LA on EVT outcomes ([22, 23]). Both studies demonstrated that non-LA was associated with better clinical outcomes. Nevertheless, the lower reperfusion rates in the LA ± CS group might influence this result. Inconsistent with that, LA demonstrated better functional outcomes at 90-day follow-up in this study. Despite similar reperfusion rates achieved in the LA and GA groups, LA showed a significantly shorter duration of time workflow. This result highlighted the importance of time workflow in modifying the outcome in different anesthesia approaches.

This study could not conclude which anesthesia approach is the best for EVT. However, we recommended that the procedure for anesthesia should be individualized according to the preoperative integrative assessment of the status of the patient. Non-GA, particularly LA, is first recommended. However, if the conditions were not allowed, there should be no argument for choosing GA. In the circumstances, attempts should be made to avoid the delay of the anesthesia procedure and hypotension to optimize the treatment outcomes.

This study has several limitations. First, the nonrandomized design. Despite using propensity score analysis to minimize the impact of confounding factors, other unmentioned factors may also impact the treatment outcome. Second, the small sample size and this study is limited to the Chinese population. Thus, this result could not be generalized to the global population. Third, LA is the first recommended anesthesia approach and GA was preferred in patients with more severe stroke. Therefore, there was a high probability of selection bias, which may affect the treatment result.

**CONCLUSION**

Our multicenter study data suggest that LA ± CS could be superior to GA for those who achieved successful recanalization. Future trials are needed to determine
the best anesthetic approach for AIS-LVO in different patient stratification.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Ethics Committee of Beijing Tiantan Hospital. The patients/participants provided their written informed consent to participate in this study.

**REFERENCES**

1. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Linssma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med.* (2015) 372:11–20. doi: 10.1056/NEJMoa1411587
2. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Charilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med.* (2015) 372:1009–18. doi: 10.1056/NEJMoa1414792
3. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med.* (2015) 372:1019–30. doi: 10.1056/NEJMoa1414905
4. Jovin TG, Chamarro A, Cobo E, de Miquel MA, Molina CA, Rosvira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med.* (2015) 372:2296–306. doi: 10.1056/NEJMoa1503780
5. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs t-PA alone in stroke. *N Engl J Med.* (2015) 372:2283–95. doi: 10.1056/NEJMoa1505061
6. Schonengerber S, Ulhmann L, Hacke W, Schiebel S, Mundijyanaparuth S, Purnickner JC, et al. Effect of conscious sedation vs general anesthesia on early neurological improvement among patients with ischemic stroke undergoing endovascular thrombectomy: a randomized clinical trial. *JAMA.* (2016) 316:1986–96. doi: 10.1001/jama.2016.16623
7. Lowhagen Henden P, Rentzos A, Karlsson JE, Rosengren L, Leiram B, Sundeman H, et al. General anesthesia versus conscious sedation for endovascular treatment of acute ischemic stroke: the anstroke trial (anesthesia during stroke). *Stroke.* (2017) 48:1601–7. doi: 10.1161/STROKEAHA.117.016554
8. Simonsen CZ, Yoo AJ, Sorensen LH, Juul N, Johnsen SP, Andersen G, et al. Effect of general anesthesia and conscious sedation during endovascular therapy on infantc growth and clinical outcomes in acute ischemic stroke: a randomized clinical trial. *JAMA Neurol.* (2018) 75:470–7. doi: 10.1001/jamaneurol.2017.4474
9. Schonengerber S, Henden PL, Simonsen CZ, Ulhmann L, Klose C, Pfaff JAR, et al. Association of general anesthesia vs procedural sedation with functional outcome among patients with acute ischemic stroke undergoing thrombectomy: a systematic review and meta-analysis. *JAMA.* (2019) 322:1283–93. doi: 10.1001/jama.2019.11485
10. Campbell BCV, van Zwam WH, Goyal M, Menon BK, Dippel DWJ, Demchuk AM, et al. Effect of general anaesthesia on functional outcome in patients with anterior circulation stroke having endovascular thrombectomy versus standard care: a meta-analysis of individual patient data. *Lancet Neurol.* (2018) 17:47–53. doi: 10.1016/S1474-4422(17)30407-6
11. Powers CJ, Dornbos III D, Mlynash M, Galati D, Torbey M, Nimjee SM, et al. Thrombectomy with conscious sedation compared with general anesthesia: a defuse 3 analysis. *AJNR Am J Neuroradiol.* (2019) 40:1001–5. doi: 10.3174/ajnr.A6059
12. Huo X, Ma N, Mo D, Gao F, Yang M, Wang Y, et al. Acute ischaemic stroke cooperation group of endovascular treatment (ANGEL) registry: study protocol for a prospective, multicentre registry in China. *Stroke Vasc Neurol.* (2019) 4:57–60. doi: 10.1136/svn-2018-000188
13. Peng Y, Wu Y, Huo X, Wu P, Zhou Y, Li J, et al. Endovascular therapy for acute ischemic stroke trial, outcomes of anesthesia selection in endovascular treatment of acute ischemic stroke. *J Neurosurg Anesthesiol.* (2019) 31:43–5. doi: 10.1097/ANA.0000000000000500
14. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. *ASPECTS* study group. Alberta stroke programme early CT score. *Lancet.* (2000) 355:1670–4. doi: 10.1016/S0140-6736(00)02237-6
15. Zhu F, Hossu G, Soudant M, Richard S, Achit H, Beguinet M, et al. Effect of emergent carotid stenting during endovascular therapy for acute anterior circulation stroke patients with tandem occlusion: A multicenter, randomized, clinical trial (TITAN) protocol. *Int J Stroke.* (2021) 16:342–48. doi: 10.1177/1747493020929948
16. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, et al. Definitions for use in a multicenter clinical trial. *TOAST.* Trial of org 10172 in acute stroke treatment. *Stroke.* (1993) 24:35–41. doi: 10.1161/108.1.24.1.135
17. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. *Lancet.* (1998) 352:1245–51. doi: 10.1016/S0140-6736(98)0020-9
18. Zaidat OO, Yoo AJ, Khatri P, Tomskick TA, von Kummer R, Saver JL, et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. *Stroke.* (2013) 44:2630–63. doi: 10.1161/STROKEAHA.113.01972
19. McDonald JS, Brinjikji W, Rabinstein AA, Cloft HJ, Lanzino G, Kallmes DF. Conscious sedation versus general anaesthesia during mechanical thrombectomy for stroke: a propensity score analysis. *J Neurointerv Surg.* (2015) 7:789–94. doi: 10.1136/neurintsurg-2014-01373
20. Bekelis K, Missios S, MacKenzie TA, Tjoumakaris S, Jabbour P. Anesthesia technique and outcomes of mechanical thrombectomy in patients with acute ischemic stroke. *Stroke.* (2017) 48:361–6. doi: 10.1161/STROKEAHA.116.015343
21. Eker OF, Saver JL, Goyal M, Jahan R, Levy EI, Nogueira RG, et al. Impact of anesthetic management on safety and outcomes following mechanical

**AUTHOR CONTRIBUTIONS**

FC and QZ supervised and performed quality control for the study. HH performed statistical analysis and acquired the data and wrote the manuscript with input from all the co-authors. All the authors contributed to the article and approved the submitted version of the manuscript.

**FUNDING**

This study was supported by the National Key Research and Development Program of China, grant no. 2016YFC1301500.
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Han, Wang, Wang, Sun, Wang, Gong, Huo, Zhu and Che. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.